Onkológia 6/2013

Current recommendations for bisphosphonates therapy in cancer patients

Bone health and maintenance of bone integrity are important components of comprehensive cancer care in both early and late stages of disease. Risk factors for osteoporosis are increased in patients with cancer, especially women with early breast cancer treated with aromatase inhibitors, men with prostate cancer receiving androgen-deprivation therapy. In both cases there is a risk of cancer therapy induced bone loss. The skeleton is a common site of metastatic cancer recurrence and skeletal-related events are the cause of significant morbidity. Bisphosphonates have their place in prevention as well as in therapy.

Keywords: bone health, breast cancer, aromatase inhibitors, prostate cancer, androgen-deprivation therapy, cancer therapy induced bone loss, skeletal-related events.